F233: Intervention Visits 3 & 4, version 01/06/05 (B)



	Section	A: General Study Info	ormation for Office U	Jse Only:				
A1. Study ID#:	Label		A2. Visit # Interv	entionINT3	INT4			
A3. Date Visit Completed:/ A4. Interventionist's initials: (must be the Interventionist who completed the visit)								
A5. Date Form Completed://								
SECTION B: Drug Intervention								
SECTION D. Ding Intervention								
B1. Does the patient report taking any of the "Need To Know" drugs since her last visit? Yes 1								
No								
B1a. List	these medications here:				_			
Drug Adhere	ence							
B2	2. Detrol LA 4mg	B2a.	B2b.	B2c.	B2d.	B2e.		
	# of 4 mg capsules taken ce the last Visit:	Start Date	Stop Date (if still taking, code 01/01/010	# Remaining	# Recovered	# Dispensed		
(IF	ZERO, SKIP TO B3)	MONTH DAY YEAR	MONTH DAY TEAR					
В3	3. Detrol LA 2mg	B3a.	B3b.	В3с.	B3d.	B3e.		
Record the # of 2 mg capsules taken since the last Visit:		Start Date	Stop Date (if still taking, code 01/01/010	Remaining	# Recovered	# Dispensed		
(IF	ZERO, SKIP TO B4)	MONTH DAY - YEAR -	MONTH DAY TEAR					
B4. Did the patient take Detrol at the same time most days? Yes								
B5. Were any interventions initiated for bothersome "yes" symptoms reported on the Symptoms Checklist (since the last visit and including today)? Yes								
D.(
B6. Record the symptom(s) and code(s) and the intervention(s) and code(s) for each bothersome "yes" symptom from the Symptoms Checklist. (See Symptom and Intervention Code Attachment).								
	i. SYMPTOM NAME		ODE iii. I	iii. INTERVENTION iv. CODE		CODE		
a.								
b.								

Affix ID Label Here

SEC	TION C: Abstraction of Key Elements from the Bladder Diary (All patients)
C1.	Average # of leaks per week: leaks / week
C2.	Average # of voids per 24 hour period voids / day
C3.	What is the patient's treatment group assignment ?
	Drug
	Drug and Behavior2
SEC	TION D: Summary of Key Elements of the Behavioral Intervention (Combination Patients Only)
D1.	Did the patient perform 5 consecutive pelvic floor muscle contractions?
	Yes 1 No
D2.	Was she able to minimize Valsalva and excessive accessory muscle contraction?
	Yes 1 No
D3.	Did the patient report she used the urge suppression strategy?
	Yes 1 No
	D3a. Did she report it worked for her?
	Yes2
D4.	Did the patient report she used the urge avoidance strategy?
	Yes
	D4a. Did she report it worked for her?
	Yes 1 No
D5.	Did the patient report she used the stress strategy ?
D 3.	Yes
	D5a. Did she report it worked for her? Yes
D.(
D6.	Did the patient report she was able to delay voiding at least 10 minutes by using the urge strategy ?
	Yes
D7.	How long did the visit last? minutes
	(COUNT ONLY THE ACTUAL TIME SPENT IN-PERSON W/ INTERVENTIONIST.)
D8.	Record the number of minutes spent with the patient between visits minutes
	INT TIME SPENT WITH PATIENT IN PHONE CONTACTS OR IN-PERSON BETWEEN STUDY VISITS. DO NOT COUNT MINUTES IT MAKING OR RESCHEDULING APPOINTMENTS.)

SYMPTOM AND INTERVENTION CODE ATTACHMENT

	SYMPTOM CODES				
01	pain or burning with urination				
02	blood in your urine				
03	difficulty emptying your bladder				
04	difficulty starting your urine stream				
05	skin rash				
06	nausea				
07	heartburn				
08	dizziness				
09	confusion or difficulty thinking clearly				
10	sore throat				
11	dry mouth				
12	blurred vision				
13	abdominal pain				
14	constipation				
15	diarrhea				
16	pelvic muscle soreness				
17	insomnia				
18	fever				
19	drowsiness				
20	headache				

INTERVENTION			
120	Dry mouth handout		
121	Constipation handout		
122	Decrease study drug dose to 2 mg		
123	Stopped study drug		
999	Other		